Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1995

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Does low-dose combination oral contraceptive use affect uterine size or

menstrual flow in premenopausal women with leiomyomas?

AUTHORS

Friedman AJ; Thomas PP

SOURCE

OBSTETRICS AND GYNECOLOGY. 1995 Apr;85(4):631-5.

ABSTRACT

A one-year prospective study involving 82 premenopausal women with confirmed leiomyomas failed to detect any

significant differences between users and non-users of low-dose monophasic oral contraceptives (OCs) in terms of

uterine size or menstrual flow duration. The 50 study subjects took an OC containing 30-35 mg of ethinyl estradiol in

combination with a variety of progestins. During the 12 month treatment period, 5 (10%) OC users demonstrated an

increase greater than 25% in ultrasonographically assessed uterine volume and 4 (8%) experienced a decrease

exceeding 25%. Among the 32 controls, these rates were 9% and 3%, respectively. In the OC group, the mean

duration of menstrual flow decreased by 1.4 days and the mean hematocrit increased by 2%; there were no

corresponding changes among controls. These findings suggest that there may be no medical basis for the practice

of withholding OCs from women with leiomyomas due to concerns that estrogen will stimulate tumor growth.

(PubHealth.info Document ID: CONT2T 2544-06)

PubHealth.info NOTE: The author(s) of this article titled, "Does low-dose combination oral contraceptive use affect

uterine size or menstrual flow in premenopausal women with leiomyomas?", is(are) Friedman AJ; Thomas PP. The

source of this article is "OBSTETRICS AND GYNECOLOGY. 1995 Apr;85(4):631-5.". This article was published in

1995 in English language(s). (PubHealth.info® Document ID: CONT2T 2544-06. All rights reserved with

PubHealth.info) PIN: 7544

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.